Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-971-6 | CAS number: 2305-05-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- (Q)SAR
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification
- Objective of study:
- toxicokinetics
- Qualifier:
- according to guideline
- Guideline:
- other: QSAR
- Preliminary studies:
- 5-octyldihydrofuran-2(3H)-one is to be a lactone compound. It almost couldn’t dissolve into water with a water solubility of 0.06 g/L. Moreover, its experimental oil-water partition coefficient LogP value is 2.7, meaning a normal fat-soluble level. We predicted toxicokinetic (TK) properties of 5-octyldihydrofuran-2(3H)-one by taking advantage of both ACD/ADME1 and DS/ADMET software packages2, respectively, in combination with literature reports of similar compound’s pharmacokinetics.
- Details on absorption:
- ACD/ADME
Maximum passive absorption: 100%;
Transcellular route: 100%;
Paracellular route: 0%.
Permeability
Human Jejunum Scale (pH 6.5):8.76´10-4cm/s;
Absorption rate:ka=0.060min-1.
Caco-2 (pH7.4, rpm 500)to predict cell membrane permeability using Caco-2 model;
Pe:238´10-6cm/s;
Transcellular route: 100 %;
Paracellular route: 0 %.
The ACD/ADME-HIA calculated data indicated that the predicted compound could be absorbed in small intestine by passive absorption rapidly. In fact, when the concentration in gastrointestinal tract is more than in blood, the compound would be absorbed by passive absorption mainly. The small molecular size, proper lipid solubility and low molecular weight of 5-octyldihydrofuran-2(3H)-one would make this compound pass the intestinal easily. Furthermore, it has been reported that the similar compound 1,4-butyrolactone (Figure 2, similarity coefficient: 0.79) could be absorbed in rat’s gastrointestinal tract. Hence, it would be rational to predict 5-octyldihydrofuran-2(3H)-one to be absorbed in gastrointestinal tract rapidly.
DS/ADMET
DS/ADMET predicted ADMET_AlogP98 of 3.914, level, 0. Level 0 represented 5-octyldihydrofuran-2(3H)-one could be absorbed in jejunum, which was accordant with above ACD/ADME-Absorption prediction. - Details on distribution in tissues:
- ACD/ADME
Plasma Protein Binding Ratio (PPB%): 89 %, RI=0.54.
LogKaHSA: 4.61. The parameter represents the binding constant between compound and human serum albumin (HSA). RI=0.34.
Generally, the binding rate more than 95% means a high binding ratio on plasma protein, 90% to 95% for a moderate binding ratio, and less than 90% for a low binding ratio. ACD/ADME-distribution model calculated data indicated that 5-octyldihydrofuran-2(3H)-one may bind with plasma protein in vivo with a low binding ratio less than 90%7. In the meantime, this compound would not bind tightly with the human albumin, since serum protein prefers a weakly-acidic compound8. - Details on excretion:
- ACD/ADME
According to above ACD/ADME-metabolism predictions, 5-octyldihydrofuran-2(3H)-one could be metabolized into 4-hydroxydodecanoic acid under hydrolysis or other hydroxylic compounds under hydroxylation, and both 4-hydroxydodecanoic acid and hydroxylic compound with improved water solubility may be excreted via urine. Furthermore, the formed 4-hydroxydodecanoic acid may be transferred to CO2, breathed out via respiratory system, under decarboxylation. - Details on metabolites:
- ACD/ADME
The predicted data from ACD/ADME indicated that the lactone part of this compound could be hydrolyzed to be a r-hydroxyl acid. Aliphatic carbons, typically C2, C3, C4, C5, C6, and C7, could be hydroxylated with highly predicted reaction probability and score to get corresponding hydroxyl compounds. As reported10, above-mentioned similar compound 1,4-butyrolactone was actually metabolized to get 4-hydroxybutanoic acid in vivo, and 4-hydroxybutanoic acid was further transferred to form CO2, exhaled via respiratory system, under a decarboxylic reaction. Based on above discussion, it would be rational to predict 5-octyldihydrofuran-2(3H)-one hydrolyzed to generate 4-hydroxydodecanoic acid, further forming CO2, or hydroxylated at C2, C3, C4, C5, C6, or C7 to get corresponding hydroxyl compounds. - Bioaccessibility (or Bioavailability) testing results:
- ACD/ADME
Oral bioavailability: < 30%. Reliability: 0.650.
ACD/ADME predicted that 5-octyldihydrofuran-2(3H)-one would have a low level of oral bioavailability with a relatively-high reliability. The very low water solubility and relatively low LogP value may make 5-octyldihydrofuran-2(3H)-one have a low oral bioavailability. - Conclusions:
- In summary, both ACD/ADME and DS/ADMET were respectively applied to predict TK properties of 5-octyldihydrofuran-2(3H)-one. According to estimated data from two different software packages in combination with literature-reported data of the similar compound, it was predicted that 5-octyldihydrofuran-2(3H)-one could be absorbed in small intestine. It could pass the BBB moderately. The compound would have a low level of oral bioavailability less than 30%. Furthermore, 5-octyldihydrofuran-2(3H)-one could bind with plasma protein in blood with a low binding ratio less than 90%, and it would not be an inhibitor or substrate of P-gp. Moreover, it was also predicted that the compound would not be an inhibitor of CYP450. 5-octyldihydrofuran-2(3H)-one might be metabolized into 4-hydroxydodecanoic acid or other hydroxyl compounds, which might be excreted via urine, with improved water solubility. The formed 4-hydroxydodecanoic acid might be further transferred into CO2, exhaled in respiratory system.
Reference
ACD/ADME
BBB permeability
LogPS: -1.2. This parameter represents the speed of passing BBB. The predicted value is larger, the rate is faster.
LogBB: 0.01. This parameter represents the ratio of compound between brain and blood under the steady state conditions. The predicted value is greater, the amount in brain is more. As reported, a compound with a LogBB value larger than 0.33 may possess high BBB permeability, and the LogBB value less than -0.1 indicates the compounds are difficult to pass the BBB.5-octyldihydrofuran-2(3H)-onewas predicted to have a LogBB value less than 0.33, suggesting a moderate BBB permeability.
Log (PS*fu, brain): -2.1. This parameter represents blood-brain equilibrium constant. The predicted data indicated this compound could distribute into brain with a large amount.
ACD/ADME-predicted data indicated that this compound might pass the BBB moderately. Actually, it has been reported that a compound possessing a LogP value between 3 and 5 would be relatively easy to pass the BBB. Although5-octyldihydrofuran-2(3H)-one has a very low water solubility of 0.06g/L, itsLogP value of 2.7 might have it to pass the BBB without an easy way.
P-gp Specificity
P-gp Inhibitors: Non inhibitor;
P-gp Substrate: Non substrate;
Reliability: high.
The low molecular weight, less than 250, of5-octyldihydrofuran-2(3H)-onemay lead this compound unfavorably binding on P-gp to be an inhibitor or substrate of P-gp.
CYP450 Inhibitor
Non-Inhibitor of CYP450
It has been reported that 1,4-butyrolactone also could be metabolized by the enzyme. Hence, the predicted compound 5-octyldihydrofuran-2(3H)-onemay not be an inhibitor of enzyme neither, and could be metabolized by corresponding enzyme.
DS/ADMET
BBB Level
DS/ADMET predicted the LogBB of 0.641, Level 1, indicating5-octyldihydrofuran-2(3H)-onecould pass the BBB moderately. The result was congruent with above ACD/ADME-BBB predictions.
ADMET_CYP2D6
ADMET_CYP2D6_Probability was predicted to be0.069, Level 0. Level 0meant5-octyldihydrofuran-2(3H)-one would not be an inhibitor of CYP2D6, which was consistent with ACD/ADME-P450predictions.
ADMET_PPB_Level
DS/ADMET predicted ADMET_AlogP98 of 3.914 and level 0, suggesting that5-octyldihydrofuran-2(3H)-one’sbinding ratio on plasma proteins less than 90%. As ACD/ADME-Distributionpredictions, DS/ADMET also suggested that5-octyldihydrofuran-2(3H)-onecould bind with plasma protein in a relatively low level.
Description of key information
Key value for chemical safety assessment
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.